Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes
Status:
Enrolling by invitation
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to switch from insulin to oral sulfonylurea in patients with
apparent type 1 diabetes or maturity onset diabetes in the young that are insulin treated.
The molecular cause will be DNA variants in the HNF1A, HNF4A, or HNF1B genes that are of
unknown significance (VUS, class 3) or known to be pathogenic (class 4 and 5).